Serum HBsAg changes in HBeAg positive chronic hepatitis B patients with continuous viral load reductions during treatment with adefovir or peg-interferon-α-2a
Serum HBsAg changes in HBeAg positive chronic hepatitis B patients with continuous viral load reductions during treatment with adefovir or peg-interferon-α-2a
复制标题
在阿德福韦或聚乙二醇干扰素 α-2a 治疗期间，HBeAg 阳性慢性乙型肝炎患者的血清 HBsAg 发生变化，且病毒载量持续降低。
DOI：
10.1016/j.antiviral.2008.09.005
复制
发表时间：
2009-01-01
影响因子：
7.6
通讯作者：
Hou, Jinlin
中科院分区：
文献类型：
--
作者：
Chen, Jinjun;Wang, Zhanhui;Hou, Jinlin
慢性B型肝炎患者在抗病毒治疗下发生B型肝炎表面抗原（HBsAg）丢失的情况很少见，这些患者的血清HBsAg动态尚不可用。本文观察了31例用阿德福韦酯或23例用聚乙二醇干扰素-α-2a治疗的B e抗原（HBeAg）阳性慢性B型肝炎患者血清HBsAg的变化。使用Abbott Architect HBsAg检测试剂盒定量血清HBsAg。在治疗的前12周内，阿德福韦酯和聚乙二醇干扰素-a-2a的HBsAg水平显著降低，中位变化分别为-397.0 IU/ml和-555.4 IU/ml（分别为p = 0.005和0.001）。超过12周后，即使在两组中持续病毒复制抑制的患者中，也没有发现HBsAg进一步显著降低。在两个治疗组的大多数患者中观察到三种不同的HBsAg变化模式：双相模式（从基线至第12周HBsAg快速降低）;上升模式（第12周HBsAg水平高于基线）;和波浪模式（从基线至第12周HBsAg降低，随后在第24周或第28周复发）。这些结果可能为抗病毒治疗下HBsAg丢失的异常发生提供可能的机制。(C)2008 Elsevier B. V.保留所有权利。
Hepatitis B surface antigen (HBsAg) loss under antiviral therapy is rare in chronic hepatitis B patients and the dynamics of serum HBsAg in these patients are not available. The changes in serum HBsAg following treatment with adefovir (n = 31) or peg-interferon-alpha-2a (n = 23) were studied in hepatitis B e-antigen (HBeAg) positive chronic hepatitis B patients. Abbott Architect HBsAg assay was used to quantify serum HBsAg. HBsAg levels were significantly decreased during the first 12 weeks of treatment with median change of -397.0 IU/ml and -555.4 IU/ml, respectively for adefovir and peg-interferon-a-2a (p = 0.005 and 0.001, respectively). Beyond 12 weeks, no further significant HBsAg reductions were found even in patients with sustained viral replication inhibition in either group. Three distinct patterns of HBsAg changes were observed in most patients in both treatment groups: biphasic pattern (rapid HBsAg reduction from baseline to week 12): assurgent pattern (higher HBsAg level at week 12 than at baseline); and wavy pattern (HBsAg reduction from baseline to week 12, followed by relapse at week 24 or week 28). These results might offer insights into the possible mechanism(s) underlying the unusual occurrences of HBsAg loss under antiviral therapy. (C) 2008 Elsevier B.V. All rights reserved.